Erenumab

CHEMBL3833329 Phase 4 ได้รับการอนุมัติ Antibody

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This monthly injectable antibody blocks the CGRP receptor, preventing the signaling that triggers migraine attacks. It is used for the preventive treatment of migraine in adults.

ด้านการรักษา

Neurology Migraine

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

This monthly injectable antibody blocks the CGRP receptor, preventing the signaling that triggers migraine attacks. It is used for the preventive treatment of migraine in adults.

Yes, Erenumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3833329. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

กำลังมองหาข้อมูลที่เข้าใจง่ายสำหรับผู้ป่วยอยู่ใช่ไหม?

Erenumab บน PillFYI

ข้อมูลด่วน

คำพ้องความหมาย: 1

ลิงก์ภายนอก

ChEMBL CHEMBL3833329

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.